Waters (NYSE:WAT) Price Target Raised to $525.00

Waters (NYSE:WAT) had its target price upped by Royal Bank Of Canada from $475.00 to $525.00 in a research report report published on Wednesday morning,Benzinga reports. They currently have an outperform rating on the medical instruments supplier’s stock.

A number of other equities research analysts have also weighed in on the stock. HSBC lifted their target price on shares of Waters from $450.00 to $455.00 and gave the company a “buy” rating in a research note on Tuesday, September 1st. Wells Fargo & Company increased their price target on shares of Waters from $370.00 to $400.00 and gave the stock an “equal weight” rating in a research note on Wednesday, August 5th. Leerink Partners increased their price target on shares of Waters from $420.00 to $450.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 5th. Weiss Ratings upgraded shares of Waters from a “hold (c-)” rating to a “hold (c)” rating in a report on Thursday, October 8th. Finally, Wall Street Zen upgraded Waters from a “hold” rating to a “buy” rating in a report on Monday, October 26th. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, Waters presently has a consensus rating of “Moderate Buy” and an average price target of $475.48.

Waters Trading Up 1.1%

WAT stock traded up $4.84 on Wednesday, reaching $457.92. The company’s stock had a trading volume of 695,768 shares, compared to its average volume of 995,254. The business has a fifty day simple moving average of $434.72 and a two-hundred day simple moving average of $372.24. Waters has a 12-month low of $282.77 and a 12-month high of $482.28. The firm has a market cap of $44.99 billion, a PE ratio of 196.53, a PEG ratio of 2.62 and a beta of 1.16. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.29 and a current ratio of 1.86.

Waters (NYSE:WAT) last released its quarterly earnings results on Tuesday, November 3rd. The medical instruments supplier reported $4.10 earnings per share for the quarter, beating the consensus estimate of $4.00 by $0.10. The business had revenue of $1.77 billion for the quarter, compared to analysts’ expectations of $1.75 billion. Waters had a net margin of 3.58% and a return on equity of 11.27%. The firm’s revenue for the quarter was up 120.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $3.40 earnings per share. As a group, research analysts forecast that Waters will post 14.65 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. California Public Employees Retirement System grew its stake in shares of Waters by 25.4% during the 1st quarter. California Public Employees Retirement System now owns 138,423 shares of the medical instruments supplier’s stock valued at $41,222,000 after purchasing an additional 28,074 shares during the period. Dudley & Shanley Inc. grew its position in Waters by 101.3% during the second quarter. Dudley & Shanley Inc. now owns 23,590 shares of the medical instruments supplier’s stock valued at $8,847,000 after buying an additional 11,870 shares during the period. Ramsay Stattman Vela & Price Inc. bought a new stake in Waters during the first quarter valued at approximately $942,000. Hahn Capital Management LLC purchased a new stake in Waters during the first quarter valued at approximately $1,490,000. Finally, Handelsbanken Fonder AB raised its position in Waters by 93.1% in the second quarter. Handelsbanken Fonder AB now owns 93,653 shares of the medical instruments supplier’s stock worth $35,124,000 after acquiring an additional 45,145 shares during the period. 94.01% of the stock is currently owned by institutional investors.

More Waters News

Here are the key news stories impacting Waters this week:

• Positive Sentiment: Waters reported $1.77 billion in third-quarter 2026 revenue and raised its full-year guidance, signaling improved expectations for the business. Waters Corporation Reports $1.77 Billion in Third Quarter 2026 Revenue and Raises Full-Year Guidance
• Positive Sentiment: The company agreed to acquire MOBILion Systems, expanding its mass spectrometry and AI-powered proteomics capabilities. The strategic fit could broaden Waters’ technology offering, though the reported item does not quantify the deal’s financial impact. Waters Corporation Acquires MOBILion Systems
• Positive Sentiment: JPMorgan, Barclays, KeyCorp, TD Cowen, Citigroup, and RBC issued reports indicating higher price targets or strong potential appreciation, reinforcing a favorable analyst outlook. JPMorgan price target Barclays outlook KeyCorp outlook TD Cowen price target Citigroup price target RBC outlook

Waters Company Profile

Waters Corporation develops and supplies analytical instruments, software, and consumables used to identify, measure, and characterize chemical and biological materials. Its products include liquid chromatography and mass spectrometry systems, which help customers analyze complex samples.

The company serves pharmaceutical and biotechnology businesses, academic and government laboratories, and customers in fields such as food, environmental testing, and materials science. Waters operates internationally, with customers and operations across multiple regions.

Founded in 1958 by James L.